

## **Mirtazapine Disintegrating Formulation**



 Version
 Revision Date:
 SDS Number:
 Date of last issue: 23.03.2020

 4.4
 01.10.2020
 51106-00016
 Date of first issue: 23.01.2015

#### **SECTION 1. PRODUCT AND COMPANY IDENTIFICATION**

Product name : Mirtazapine Disintegrating Formulation

Manufacturer or supplier's details

Company : Organon & Co.

Address : 30 Hudson Street, 33nd floor

Jersey City, New Jersey, U.S.A 07302

Telephone : 551-430-6000

Emergency telephone : 215-631-6999

E-mail address : EHSSTEWARD@organon.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

#### **SECTION 2. HAZARDS IDENTIFICATION**

**GHS Classification** 

Acute toxicity (Oral) : Category 4

Reproductive toxicity : Category 2

Specific target organ toxicity - :

repeated exposure (Oral)

Category 2 (Nervous system)

Short-term (acute) aquatic

hazard

Category 3

Long-term (chronic) aquatic

hazard

Category 3

**GHS** label elements

Hazard pictograms





Signal Word : Warning

Hazard Statements : H302 Harmful if swallowed.

H361fd Suspected of damaging fertility. Suspected of

damaging the unborn child.

H373 May cause damage to organs (Nervous system) through

prolonged or repeated exposure if swallowed. H412 Harmful to aquatic life with long lasting effects.



## **Mirtazapine Disintegrating Formulation**



Version Revision Date: SDS Number: Date of last issue: 23.03.2020 4.4 01.10.2020 51106-00016 Date of first issue: 23.01.2015

Precautionary Statements : Prevention:

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read

and understood.

P260 Do not breathe dust.

P264 Wash skin thoroughly after handling.

P270 Do not eat, drink or smoke when using this product.

P273 Avoid release to the environment.

P280 Wear protective gloves/ protective clothing/ eye protec-

tion/ face protection.

Response:

P301 + P312 + P330 IF SWALLOWED: Call a POISON

CENTER/ doctor if you feel unwell. Rinse mouth.

P308 + P313 IF exposed or concerned: Get medical advice/

attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste

disposal plant.

#### Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

### **SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture

#### Components

| Chemical name   | CAS-No.    | Concentration (% w/w) |  |
|---|------------|-----------------------|--|
| (+/-)-1,2,3,4,10,14b-Hexahydro-2-<br>methylpyrazino[2,1-a]pyrido[2,3-<br>c][2]benzazepine | 85650-52-8 | >= 20 -< 25           |  |
| Citric acid   | 77-92-9    | >= 1 -< 5             |  |
| Cellulose   | 9004-34-6  | >= 1 -< 5             |  |
| Magnesium stearate  | 557-04-0   | >= 1 -< 5             |  |

#### **SECTION 4. FIRST AID MEASURES**

General advice : In the case of accident or if you feel unwell, seek medical

advice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled : If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.



## **Mirtazapine Disintegrating Formulation**



Version Revision Date: SDS Number: Date of last issue: 23.03.2020 4.4 01.10.2020 51106-00016 Date of first issue: 23.01.2015

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : If in eyes, rinse well with water.

Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

Never give anything by mouth to an unconscious person.

Most important symptoms and effects, both acute and

delayed

Harmful if swallowed.

Suspected of damaging fertility. Suspected of damaging the

unborn child.

May cause damage to organs through prolonged or repeated

exposure if swallowed.

Contact with dust can cause mechanical irritation or drying of

the skin.

Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

#### **SECTION 5. FIRE-FIGHTING MEASURES**

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

Specific hazards during fire

fighting

Avoid generating dust; fine dust dispersed in air in sufficient

concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod-

ucts

Carbon oxides

Nitrogen oxides (NOx)

Metal oxides

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment.

Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment :

for fire-fighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

#### **SECTION 6. ACCIDENTAL RELEASE MEASURES**

Personal precautions, protec: :

tive equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).



## Mirtazapine Disintegrating Formulation

ORGANON

Version **Revision Date:** SDS Number: Date of last issue: 23.03.2020 01.10.2020 51106-00016 Date of first issue: 23.01.2015 4.4

Avoid release to the environment. **Environmental precautions** 

> Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up Sweep up or vacuum up spillage and collect in suitable

container for disposal.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items

employed in the cleanup of releases. You will need to determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

#### **SECTION 7. HANDLING AND STORAGE**

Technical measures Static electricity may accumulate and ignite suspended dust

causing an explosion.

Do not breathe dust.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres.

Local/Total ventilation Advice on safe handling Use only with adequate ventilation.

Do not swallow.

Avoid contact with eyes.

Avoid prolonged or repeated contact with skin.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure

assessment

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Keep in properly labeled containers. Conditions for safe storage

Store locked up.

Store in accordance with the particular national regulations.

Materials to avoid Do not store with the following product types:

Strong oxidizing agents

#### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### Ingredients with workplace control parameters

| Components | CAS-No. | Value type | Control parame-    | Basis |
|------------|---------|------------|--------------------|-------|
|            |         | (Form of   | ters / Permissible |       |



## **Mirtazapine Disintegrating Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 23.03.2020

 4.4
 01.10.2020
 51106-00016
 Date of first issue: 23.01.2015

|   |  | exposure)                                    | concentration              |          |  |
|---|--|--|----------------------------|----------|--|
| (+/-)-1,2,3,4,10,14b-<br>Hexahydro-2-<br>methylpyrazino[2,1-<br>a]pyrido[2,3-c][2]benzazepine | 85650-52-8   | TWA  | 25 μg/m³                   | Internal |  |
|   |  | Wipe limit                                   | 250 µg/100 cm <sup>2</sup> | Internal |  |
| Cellulose   | 9004-34-6  | CMP  | 10 mg/m <sup>3</sup>       | AR OEL   |  |
|   | Further information: Irritation  |  |                            |          |  |
|   |  | TWA  | 10 mg/m <sup>3</sup>       | ACGIH    |  |
| Magnesium stearate  | 557-04-0   | CMP  | 10 mg/m <sup>3</sup>       | AR OEL   |  |
|   | Further information: A4 - Not classifiable as a human carcinogen, Irritation |  |                            |          |  |
|   |  | TWA<br>(Inhalable<br>particulate<br>matter)  | 10 mg/m³                   | ACGIH    |  |
|   |  | TWA<br>(Respirable<br>particulate<br>matter) | 3 mg/m³                    | ACGIH    |  |

**Engineering measures**: Ensure adequate ventilation, especially in confined areas.

Minimize workplace exposure concentrations. Apply measures to prevent dust explosions.

Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or

exposure assessment demonstrates exposures outside the

recommended guidelines, use respiratory protection.

Filter type Hand protection

Particulates type

Material : Chemical-resistant gloves

Remarks : Choose gloves to protect hands against chemicals depending

on the concentration specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before

breaks and at the end of workday.

Eye protection : Wear the following personal protective equipment:

Safety goggles

Skin and body protection : Select appropriate protective clothing based on chemical

resistance data and an assessment of the local exposure

potential.

Skin contact must be avoided by using impervious protective

clothing (gloves, aprons, boots, etc).

Hygiene measures : If exposure to chemical is likely during typical use, provide

eye flushing systems and safety showers close to the



## **Mirtazapine Disintegrating Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 23.03.2020

 4.4
 01.10.2020
 51106-00016
 Date of first issue: 23.01.2015

working place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

#### **SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

Appearance : powder

Color : No data available

Odor : No data available

Odor Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : May form explosive dust-air mixture during processing,

handling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapor pressure : No data available

Relative vapor density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

: No data available

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, dynamic : No data available

Viscosity, kinematic : No data available



## **Mirtazapine Disintegrating Formulation**

♣ ORGANON

Version Revision Date: SDS Number: Date of last issue: 23.03.2020 4.4 01.10.2020 51106-00016 Date of first issue: 23.01.2015

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : No data available

#### **SECTION 10. STABILITY AND REACTIVITY**

Reactivity : Not classified as a reactivity hazard. Chemical stability : Stable under normal conditions.

Possibility of hazardous reac-

tions

May form explosive dust-air mixture during processing,

handling or other means.

Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.

Avoid dust formation.
Oxidizing agents

Incompatible materials

Hazardous decomposition

products

No hazardous decomposition products are known.

#### **SECTION 11. TOXICOLOGICAL INFORMATION**

Information on likely routes of:

exposure

Inhalation Skin contact Ingestion

Eye contact

**Acute toxicity** 

Harmful if swallowed.

**Product:** 

Acute oral toxicity : Acute toxicity estimate: 1.588 mg/kg

Method: Calculation method

### **Components:**

(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Acute oral toxicity : LD50 (Rat): 320 - 490 mg/kg

Citric acid:

Acute oral toxicity : LD50 (Mouse): 5.400 mg/kg

Acute dermal toxicity : LD50 (Rat): > 2.000 mg/kg

Method: OECD Test Guideline 402

Assessment: The substance or mixture has no acute dermal

toxicity

Cellulose:

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg



r ORGANON

## **Mirtazapine Disintegrating Formulation**

Version Revision Date: SDS Number: Date of last issue: 23.03.2020 4.4 01.10.2020 51106-00016 Date of first issue: 23.01.2015

Acute inhalation toxicity : LC50 (Rat): > 5,8 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2.000 mg/kg

Magnesium stearate:

Acute oral toxicity : LD50 (Rat): > 2.000 mg/kg

Method: OECD Test Guideline 423

Assessment: The substance or mixture has no acute oral tox-

icity

Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2.000 mg/kg

Remarks: Based on data from similar materials

Skin corrosion/irritation

Not classified based on available information.

Components:

Citric acid:

Species : Rabbit

Method : OECD Test Guideline 404

Result : No skin irritation

Magnesium stearate:

Species : Rabbit

Result : No skin irritation

Remarks : Based on data from similar materials

Serious eye damage/eye irritation

Not classified based on available information.

**Components:** 

Citric acid:

Species : Rabbit

Result : Irritation to eyes, reversing within 21 days

Method : OECD Test Guideline 405

Magnesium stearate:

Species : Rabbit

Result : No eye irritation

Remarks : Based on data from similar materials

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.



## **Mirtazapine Disintegrating Formulation**



Version Revision Date: SDS Number: Date of last issue: 23.03.2020 4.4 01.10.2020 51106-00016 Date of first issue: 23.01.2015

### **Respiratory sensitization**

Not classified based on available information.

#### **Components:**

#### Magnesium stearate:

Test Type : Maximization Test
Routes of exposure : Skin contact
Species : Guinea pig

Method : OECD Test Guideline 406

Result : negative

Remarks : Based on data from similar materials

### Germ cell mutagenicity

Not classified based on available information.

#### **Components:**

### (+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Test system: Chinese hamster lung cells

Result: negative

Test Type: unscheduled DNA synthesis assay

Test system: mammalian cells

Result: negative

Test Type: sister chromatid exchange assay

Test system: mammalian cells

Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Rat

Cell type: Bone marrow Application Route: Oral

Result: negative

Citric acid:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: in vitro micronucleus test

Result: positive

Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow

cytogenetic test, chromosomal analysis)

Species: Rat

Application Route: Ingestion



## **Mirtazapine Disintegrating Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 23.03.2020

 4.4
 01.10.2020
 51106-00016
 Date of first issue: 23.01.2015

Result: negative

Cellulose:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Ingestion

Result: negative

Magnesium stearate:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test

Result: negative

Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro

Method: OECD Test Guideline 473

Result: negative

Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Remarks: Based on data from similar materials

### Carcinogenicity

Not classified based on available information.

### **Components:**

### (+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Species : Mouse
Application Route : Oral
Exposure time : 18 month(s)

LOAEL : 200 mg/kg body weight

Result : equivocal Target Organs : Liver

Species : Rat
Application Route : Oral
Exposure time : 2 Years

LOAEL : 20 mg/kg body weight

Result : equivocal Target Organs : Liver, Thyroid

Cellulose:

Species : Rat Application Route : Ingestion



## **Mirtazapine Disintegrating Formulation**



Version **Revision Date:** SDS Number: Date of last issue: 23.03.2020 51106-00016 Date of first issue: 23.01.2015 4.4 01.10.2020

Exposure time 72 weeks Result negative

### Reproductive toxicity

Suspected of damaging fertility. Suspected of damaging the unborn child.

### **Components:**

(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Effects on fertility Test Type: Fertility/early embryonic development

Species: Rat

**Application Route: Oral** 

Fertility: LOAEL: 15 mg/kg body weight

Symptoms: Effect on estrous cycle, Increase of early resorp-

tions.

Result: Animal testing did not show any effects on fertility., Embryotoxic effects and adverse effects on the offspring were

detected.

Effects on fetal development Test Type: Development

Species: Rat

**Application Route: Oral** 

Developmental Toxicity: LOAEL: 100 mg/kg body weight Result: Embryotoxic effects and adverse effects on the

offspring were detected., No teratogenic effects.

Test Type: Development

Species: Rabbit Application Route: Oral

Developmental Toxicity: NOAEL: 40 mg/kg body weight Result: No adverse effects., No teratogenic effects.

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Some evidence of

adverse effects on development, based on animal

experiments.

Citric acid:

Effects on fetal development Test Type: One-generation reproduction toxicity study

Species: Rat

Application Route: Ingestion

Result: negative

Cellulose:

Effects on fertility Test Type: One-generation reproduction toxicity study

Species: Rat

Application Route: Ingestion

Result: negative

Test Type: Fertility/early embryonic development Effects on fetal development

Species: Rat

Application Route: Ingestion

Result: negative



## **Mirtazapine Disintegrating Formulation**

♣ ORGANON

Version Revision Date: SDS Number: Date of last issue: 23.03.2020 4.4 01.10.2020 51106-00016 Date of first issue: 23.01.2015

Magnesium stearate:

Effects on fertility : Test Type: Combined repeated dose toxicity study with the

reproduction/developmental toxicity screening test

Species: Rat

Application Route: Ingestion Method: OECD Test Guideline 422

Result: negative

Remarks: Based on data from similar materials

Effects on fetal development : Test Type: Embryo-fetal development

Species: Rat

Application Route: Ingestion

Result: negative

Remarks: Based on data from similar materials

#### STOT-single exposure

Not classified based on available information.

#### STOT-repeated exposure

May cause damage to organs (Nervous system) through prolonged or repeated exposure if swallowed.

### **Components:**

### (+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Routes of exposure : Ingestion

Target Organs : Nervous system

Assessment : May cause damage to organs through prolonged or repeated

exposure.

#### Repeated dose toxicity

### Components:

### (+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Species : Rat LOAEL : 120 mg/kg

Application Route : Oral
Exposure time : 13 Weeks
Target Organs : Nervous system

Species : Dog
LOAEL : 15 mg/kg
Application Route : Oral
Exposure time : 52 Weeks
Target Organs : Nervous system

Symptoms : Tremors

Species : Dog LOAEL : 20 mg/kg Application Route : Oral Exposure time : 13 Weeks

Target Organs : Nervous system, Testis



## **Mirtazapine Disintegrating Formulation**



 Version
 Revision Date:
 SDS Number:
 Date of last issue: 23.03.2020

 4.4
 01.10.2020
 51106-00016
 Date of first issue: 23.01.2015

Symptoms : Tremors

Citric acid:

Species : Rat

NOAEL : 4.000 mg/kg LOAEL : 8.000 mg/kg Application Route : Ingestion Exposure time : 10 Days

Cellulose:

Species : Rat

NOAEL : >= 9.000 mg/kg

Application Route : Ingestion Exposure time : 90 Days

Magnesium stearate:

Species : Rat

NOAEL : > 100 mg/kg
Application Route : Ingestion
Exposure time : 90 Days

Remarks : Based on data from similar materials

**Aspiration toxicity** 

Not classified based on available information.

**Experience with human exposure** 

**Components:** 

(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Ingestion : Symptoms: Drowsiness, constipation, dry mouth, asthenia,

Dizziness, Disorientation

#### **SECTION 12. ECOLOGICAL INFORMATION**

#### **Ecotoxicity**

### **Components:**

(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 6,92 mg/l

Exposure time: 96 h Method: FDA 4.11

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 19,5 mg/l

Exposure time: 48 h

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): 5,7

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201



ORGANON

## **Mirtazapine Disintegrating Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 23.03.2020

 4.4
 01.10.2020
 51106-00016
 Date of first issue: 23.01.2015

NOEC (Pseudokirchneriella subcapitata (green algae)): 3,2

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Toxicity to fish (Chronic tox-

icity)

NOEC (Pimephales promelas (fathead minnow)): 3,6 mg/l

Exposure time: 31 d

Method: OECD Test Guideline 210

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 0,32 mg/l

Exposure time: 21 d

Method: OECD Test Guideline 211

Toxicity to microorganisms : EC50 (Natural microorganism): > 1.000 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

NOEC (Natural microorganism): < 100 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Citric acid:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l

Exposure time: 96 h

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 1.535 mg/l

Exposure time: 24 h

Cellulose:

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l

Exposure time: 48 h

Remarks: Based on data from similar materials

Magnesium stearate:

Toxicity to fish : LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l

Exposure time: 48 h Method: DIN 38412

Remarks: Based on data from similar materials

Toxicity to daphnia and other :

aquatic invertebrates

EL50 (Daphnia magna (Water flea)): > 1 mg/l

Exposure time: 47 h

Test substance: Water Accommodated Fraction Method: Directive 67/548/EEC, Annex V, C.2. Remarks: Based on data from similar materials

No toxicity at the limit of solubility.

Toxicity to algae/aquatic

plants

EL50 (Pseudokirchneriella subcapitata (green algae)): > 1

mg/l

Exposure time: 72 h

Test substance: Water Accommodated Fraction

Method: OECD Test Guideline 201



## **Mirtazapine Disintegrating Formulation**

Version Revision Date: SDS Number: Date of last issue: 23.03.2020 4.4 01.10.2020 51106-00016 Date of first issue: 23.01.2015

Remarks: Based on data from similar materials

No toxicity at the limit of solubility.

NOELR (Pseudokirchneriella subcapitata (green algae)): > 1

mg/l

Exposure time: 72 h

Test substance: Water Accommodated Fraction

Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

Toxicity to microorganisms : EC10 (Pseudomonas putida): > 100 mg/l

Exposure time: 16 h

Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials

Persistence and degradability

**Components:** 

Citric acid:

Biodegradability : Result: Readily biodegradable.

Biodegradation: 97 % Exposure time: 28 d

Method: OECD Test Guideline 301B

Cellulose:

Biodegradability : Result: Readily biodegradable.

Magnesium stearate:

Biodegradability : Result: Not biodegradable.

Remarks: Based on data from similar materials

Bioaccumulative potential

**Components:** 

(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Bioaccumulation : Species: Oncorhynchus mykiss (rainbow trout)

Bioconcentration factor (BCF): 334 Method: OECD Test Guideline 305

Partition coefficient: n-

octanol/water

: log Pow: 2,78

Citric acid:

Partition coefficient: n-

: log Pow: -1,72

octanol/water

Magnesium stearate:

Partition coefficient: n-

octanol/water

log Pow: > 4



## **Mirtazapine Disintegrating Formulation**



Version Revision Date: SDS Number: Date of last issue: 23.03.2020 4.4 01.10.2020 51106-00016 Date of first issue: 23.01.2015

#### Mobility in soil

#### **Components:**

(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Distribution among environ-

: log Koc: 4,48

mental compartments

Other adverse effects

No data available

#### **SECTION 13. DISPOSAL CONSIDERATIONS**

**Disposal methods** 

Waste from residues : Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste

handling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

#### **SECTION 14. TRANSPORT INFORMATION**

#### International Regulations

### **UNRTDG**

Not regulated as a dangerous good

#### IATA-DGR

Not regulated as a dangerous good

#### **IMDG-Code**

Not regulated as a dangerous good

### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

#### **SECTION 15. REGULATORY INFORMATION**

# Safety, health and environmental regulations/legislation specific for the substance or mixture

Argentina. Carcinogenic Substances and Agents

: Not applicable

Registry.

Control of precursors and essential chemicals for the :

: Sodium hydrogencarbonate

preparation of drugs.

### International Regulations

### The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined



## **Mirtazapine Disintegrating Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 23.03.2020

 4.4
 01.10.2020
 51106-00016
 Date of first issue: 23.01.2015

#### **SECTION 16. OTHER INFORMATION**

#### **Further information**

Sources of key data used to compile the Material Safety

Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

#### Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)
AR OEL : Argentina. Occupational Exposure Limits

ACGIH / TWA : 8-hour, time-weighted average AR OEL / CMP : TLV (Threshold Limit Value)

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation: DSL - Domestic Substances List (Canada): ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance: PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific



## **Mirtazapine Disintegrating Formulation**

Version Revision Date: SDS Number: Date of last issue: 23.03.2020 4.4 01.10.2020 51106-00016 Date of first issue: 23.01.2015

context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

AR / Z8